The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes
    • eBooks

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Pathology Captures
Subscribe
Subscribe

False

The Pathologist / Issues / 2025 / December / AI Models Predict CNS Tumors From Spinal Fluid
Oncology Molecular Pathology Digital and computational pathology Liquid biopsy Omics

AI Models Predict CNS Tumors From Spinal Fluid

At AMP 2025, a South Korean research team outlined a multimodal approach that integrates CSF, DNA, and MRI data to enable early, noninvasive tumor classification.

12/04/2025 News 1 min read
  • Full Article
  • Summary
  • Takeaways

Share

5 Key Takeaways
  • 1

    AI models may enable earlier noninvasive identification of pathogenic variants in CNS tumors.

  • 2

    The study developed two machine-learning models using mutation data and MRI images from CNS tumor patients.

  • 3

    The models classified samples into glial tumors, nonglial CNS tumors, and normal tissue with strong reliability.

  • 4

    The dense neural network achieved a Matthews Correlation Coefficient of 0.8822, while the MRI model achieved 0.8525.

  • 5

    Combining model outputs improved performance in identifying pathogenic variants and tumor types.

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.

Newsletters

Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

Redefining Diagnostic Reference Standards
Molecular Pathology
Redefining Diagnostic Reference Standards

January 3, 2022

1 min read

Find out what Horizon Discovery’s diagnostic reference standards can do for your workflow

Non-invasive Prostate Cancer Screening
Molecular Pathology
Non-invasive Prostate Cancer Screening

November 5, 2014

1 min read

Can SERS accurately detect the early stages of the most common male cancer?

Sequencing Access for All
Molecular Pathology
Sequencing Access for All

January 24, 2022

1 min read

An affordable genome sequencing pipeline for low- and middle-income countries

Improving Risk Stratification
Molecular Pathology
Improving Risk Stratification

February 3, 2022

1 min read

Two genes have been identified that may be linked to prostate cancer outcomes

Affiliations:

Specialties:

Areas of Expertise:

Contributions:

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.